<DOC>
	<DOCNO>NCT00002145</DOCNO>
	<brief_summary>PRIMARY : To compare frequency time relapse Cytomegalovirus ( CMV ) gastrointestinal disease follow foscarnet induction therapy versus induction plus maintenance therapy . SECONDARY : To determine frequency time recurrence gastrointestinal symptom , response rate pathological lesion , incidence nongastrointestinal CMV disease patient population .</brief_summary>
	<brief_title>Phase III Multicenter , Open-Label , Randomized Trial Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy Gastrointestinal CMV Disease</brief_title>
	<detailed_description>Patients receive intravenous foscarnet either induction 4 week induction 4 week follow maintenance 22 week . All patient follow 26 week relapse .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>Inclusion Criteria Patients must : AIDS . CMV GI disease . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : NonGI CMV disease . Ulcerative colitis , inflammatory bowel disease , condition may interfere study result . Other GI pathogen . Concurrent Medication : Excluded : Drugs may interact foscarnet . Systemic acyclovir , ganciclovir , acyclovir prodrug . Drugs known affect renal function . Prior Medication : Excluded : Prior foscarnet extremis . Investigational agent 3TC d4T within 7 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>